ITGR

INTEGER HOLDINGS CORP

Healthcare | Mid Cap

$1.27

EPS Forecast

$431.3

Revenue Forecast

The company already released most recent quarter's earnings. We will publish our AI's next quarter's forecast around 2026-07-20

Integer Holdings ITGR Prelim 2022 Results Point to Growth Amid Leverage Build

Ticker: ITGR • EPS (GAAP) $0.49–$0.51; EPS (Non-GAAP) $1.08–$1.11 • revenue forecast for Q4: $370–$372 million; full-year revenue guidance around $1.374–$1.376 billion • earnings surprise potential as results land at the high end of prior guidance • EPS consensus not published in the release; management previews details on the February earnings call.

Preliminary financial highlights

Integer Holdings Corporation (NYSE: ITGR) disclosed preliminary results for the fourth quarter and full year ended December 31, 2022. The company framed the quarter as a continuation of what it calls a challenging yet navigable supply chain environment, with a Q4 revenue forecast of $370–$372 million, representing an 18%–19% increase year over year. Organic growth for the period is pegged at 12%–13%.

  • Fourth quarter 2022 GAAP operating income: $36–$37 million; Adjusted operating income: $56–$57 million (non-GAAP).
  • Full-year 2022 sales: $1.374–$1.376 billion; GAAP operating income: $120–$121 million; Adjusted operating income: $191–$192 million.
  • Cash flow from operations (full year): about $114–$116 million.
  • Debt profile: total debt at year-end 2022 ≈ $925–$926 million; net total debt ≈ $907–$909 million; leverage ratio around 3.5x–3.6x EBITDA, reflecting the Aran Biomedical acquisition.
  • Diluted earnings per share (Q4 2022): GAAP $0.49–$0.51; Non-GAAP $1.08–$1.11.

Management emphasized that these preliminary results are unaudited and subject to adjustments in the final year-end closing procedures. The company reiterated that it will report the full-year 2022 results and provide more detailed 2023 guidance on its February 16, 2023 earnings call, affirming the revenue guidance already communicated in its October 27, 2022 earnings release.

What this signaling portends for ITGR and peers

The headline numbers show momentum in a difficult operating backdrop, with Q4 revenue and full-year sales tracking toward the upper end of prior expectations. That a significant portion of the quarterly strength is labeled as organic growth—12%–13% in Q4—suggests the demand for Integer’s contract-manufacturing services remains durable even as the broader med-tech supply chain wrestles with volatility.

On the profitability side, the split between GAAP and non-GAAP results is notable but not unusual in specialized manufacturing. The non-GAAP trajectory—roughly $1.08–$1.11 of diluted EPS for Q4—points to meaningful cash flow generation (full-year FCF around $114–$116 million) that could support ongoing investments or deleveraging if management guides that path explicitly in February.

The debt load rose alongside the Aran Biomedical acquisition, with total debt near $925–$926 million and net debt around $907–$909 million, yielding a leverage range of 3.5x–3.6x on year-end EBITDA. That indicates a growth-at-all-costs posture funded by leverage, a calculus that pays dividends if integration milestones hit and if incremental EBITDA translates into stronger free cash flow. The acquisition’s $129 million price tag is nontrivial and will be a key focal point as the company tallies the synergy and product-mix benefits over 2023.

For investors, the absence of a published EPS consensus in the filing means the February call becomes pivotal for calibrating expectations against Wall Street models. The company’s language about meeting the high end of its earnings guidance could be read as a modest earnings surprise to its own outlook, depending on how investors weight the final year-end adjustments and the early 2023 outlook. In any case, the combination of revenue growth, a robust cash flow runway, and a higher debt posture creates a two-speed narrative: top-line momentum versus leverage and integration risk.

Sector peers—manufacturers that rely on outsourced med-tech production—will want to watch whether ITGR can sustain 2023 revenue pace in a tightening-margin landscape. If the Aran integration yields meaningful cost synergies, ITGR could demonstrate that acquisitions remain a viable engine for growth at scale; if not, the elevated debt burden may constrain capital allocation in the near term. Either way, ITGR’s results reinforce the theme that supply chain resilience and efficiency gains remain the real differentiators in medical device manufacturing.

Outlook and key questions to monitor

  • Will ITGR’s 2023 revenue forecast endure if input costs rise or supply dynamics shift again?
  • How will the Aran Biomedical integration influence margins and free cash flow in 2023?
  • What trajectory does the EPS path take as debt service pressure and potential saving initiatives unfold?
  • How does ITGR stack up against peers in terms of EBITDA growth, ROIC, and leverage discipline as more med-tech outsourcing players report results?

The February 16 earnings call will be crucial for confirming year-end metrics and for laying out the 2023 path—particularly the revenue forecast and any revised EPS targets that might shift market expectations.

Notes for readers

The company emphasizes that the results are preliminary and unaudited and may change during final close procedures. The press release frames the results as being “in the range” of prior guidance, underscoring a cautious approach to forward-looking statements in the face of ongoing macro and supply chain uncertainties.

Disclosure: This article synthesizes ITGR’s preliminary release and highlights the balance between growth initiatives funded by leverage and the accompanying risk profile. Investors should await the full-year 2022 results and the 2023 guidance on the February earnings call for a definitive read.